CAS Number: 121268-17-5
Fosamax | 121268-17-5
Alendronate Sodium (Fosamax) is a potent nitrogen-containing bisphosphonate and a first-line therapy for osteoporosis and Paget’s disease, but its clinical efficacy is severely limited by extremely low oral bioavailability (approximately 0.7%) due to its BCS Class III properties—high solubility but very poor intestinal permeability, as well as strong binding to dietary divalent cations that form non-absorbable complexes. To overcome these barriers, advanced drug delivery systems have been developed: a self-double-emulsifying drug delivery system (SDEDDS) containing phosphatidylcholine (PLG 1.1) demonstrated enhanced permeation across biomimetic membranes (88% drug transfer) and a 1.8-fold increase in urinary excretion in rats, offering a viable strategy to improve oral absorption. Additionally, polymeric nanoparticles made from cashew and angico gums (NPALD) improved the antitumor selectivity of alendronate against colorectal cancer while reducing systemic toxicity such as cholestasis and renal vasocongestion in mouse models. Solid lipid nanoparticles co-loaded with alendronate and puerarin (Pue/Ale-SLNs) achieved sustained release, high encapsulation efficiency (99.9% for alendronate), and superior restoration of bone mineral density and trabecular microstructure in osteoporotic rats compared to commercial tablets. Clinical evidence further shows that the original once-weekly Fosamax 70 mg produced a significant 8.8% increase in lumbar spine bone mineral density over 1.4 years (p=0.004), whereas a generic daily alendronate 10 mg showed only a 2.3% non-significant increase, indicating that formulation and bioequivalence differences may translate into real-world efficacy discrepancies. Collectively, these findings highlight that while alendronate sodium is therapeutically potent, its delivery systems—ranging from lipid-based nanocarriers to polymer nanoparticles—are critical determinants of its permeability, bioavailability, safety, and overall clinical success.
Product Information
HM Chemical Trading GmbH supplies industrial-grade specialty chemicals and raw materials with reliable international logistics support.
References
-
Biopharmaceutical and pharmacokinetic characterization of sodium alendronate-loaded self-double-emulsifying drug delivery systems (SDEDDS)
The comprehensive evaluation demonstrates that the PLG 1.1 SDEDDS formulation is a highly promising strategy for enhancing the oral bioavailability of sodium alendronate. It successfully combines acceptable physicochemical properties with a demonstrated ability to significantly enhance intestinal permeation, as confirmed by both biomimetic in vitro models and an in vivo rat study. The key differentiator for PLG 1.1 is the inclusion of phosphatidylcholine, which facilitates membrane interaction and drug absorption. These findings warrant further investigation, including long-term stability studies and toxicological assessment, to advance this formulation toward clinical application for improving patient compliance and therapeutic outcomes of alendronate therapy.
DOI: 10.3897/pharmacia.73.e178356 -
Sodium alendronate doped chitosan based micro hybrid scaffold enhances in situ biomimetic mineralization and promotes endogenous bone regeneration
The current method of using scaffold materials to repair bone defects still faces limitations in achieving biomimetic mineralization and endogenous bone tissue regeneration. Therefore, we have developed a novel ALN doped chitosan/hydroxyapatite (CS/ALN/nHAP) micro nano hybrid scaffold based on in situ tissue engineering principles. The addition of alendronate (ALN) increases nucleation sites, enhances biomimetic mineralization of nHAP in situ, and promotes the aggregation of endogenous stem cells. The scaffold prepared by freeze-drying showed that increasing ALN content can enhance nHAP mineralization, thereby improving mechanical strength. In vitro experiments have confirmed its excellent biological activity and cell proliferation ability. In the rat skull defect model, compared with the control group, the ALN composite scaffold significantly accelerated bone healing. Therefore, the prepared ALN doped composite scaffold can enhance the biomimetic mineralization ability of the scaffold and promote bone tissue regeneration at the defect site. In summary, this study provides a new method for biomimetic construction of porous scaffold materials, which enhances nHAP nucleation mineralization and bone repair by adding ALN, while promoting endogenous bone tissue regeneration.
DOI: 10.1016/j.ijbiomac.2025.147289